RBC Capital Reaffirms Their Buy Rating on IGM Biosciences (IGMS)
In a report released on November 8, Brian Abrahams from RBC Capital maintained a Buy rating on IGM Biosciences (IGMS – Research Report), ...
Biotech firm backs off its focus on oncology research
IGM Biosciences pivoted to autoimmune disease, reducing R&D expenses. The company reported a net loss of $61.4 million. CEO ...
Cautious Outlook for IGM Biosciences Amid Delayed Data and Financial Adjustments
Analyst Michael Ulz of Morgan Stanley maintained a Hold rating on IGM Biosciences (IGMS – Research Report), retaining the price target of ...
IGM Biosciences, Inc. (IGMS) Reports Q3 Loss, Tops Revenue Estimates
IGM Biosciences (IGMS) delivered earnings and revenue surprises of -23.17% and 123.38%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Yahoo Finance6d
IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update
MOUNTAIN VIEW, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced ...